Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Enlicitide decanoate demonstrated meaningful LDL lowering in patients with heterozygous familial hypercholesterolemia and ...

A study showed that hospitals bought by private equity firms were admitting disproportionately healthier patients with heart ...

When the amount of cholesterol in the blood is too high, hypercholesterolemia can develop, causing serious damage to the ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Currently available PCSK9-targeting therapies are Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab), ...

A new method, based on the use of molecules known as polypurine hairpins, facilitates the uptake of cholesterol by cells and ...

Topline data were announced from two phase 3 trials evaluating enlicitide decanoate for the treatment of adults with hyperlipidemia.

Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

The patients came in with high cholesterol. And it was the kind that clings stubbornly to arteries and shadows families for ...

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Scientists have discovered how pancreatic cancer cells thrive in the lungs or liver, environments that are as distinct to cells as the ocean and desert are to animals. The spread of cancer cells to ...